Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for cough: active agents.

K F Chung1, A B Chang

  • 1Royal Brompton Hospital, National Heart & Lung Institute, London, England. f.chung@ic.ac.uk

Pulmonary Pharmacology & Therapeutics
|July 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment outcomes of drug-resistant tuberculosis in Sabah, Malaysia - a retrospective cohort study.

Public health in practice (Oxford, England)·2025
Same author

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.

International journal of pediatric otorhinolaryngology·2023
Same author

Disease burden, comorbidities and antecedents of chronic cough phenotypes in Australian adults.

Pulmonology·2023
Same author

The microbiota in bronchoalveolar lavage from young children with chronic lung disease includes taxa present in both the oropharynx and nasopharynx.

Microbiome·2016
Same author

Prevalence, codetection and seasonal distribution of upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a symptom.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

Staphylococcal enterotoxin-specific IgE: a biomarker for a distinct phenotype of severe asthma?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same journal

Brain-Derived Neurotrophic Factor (BDNF) Signaling in Respiratory Disease: Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Cough is a common respiratory symptom. New drug targets are being explored to develop effective cough suppressants (antitussives) without the side effects of current opioid medications.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Neuroscience

Background:

  • Cough is a vital airway defense reflex and a frequent respiratory symptom.
  • Persistent cough links to conditions like asthma, rhino-sinusitis, and gastro-oesophageal reflux.
  • Current opioid antitussives (e.g., codeine) offer relief but cause side effects like drowsiness and dependence.

Purpose of the Study:

  • To explore novel drug targets for cough reflex modulation.
  • To identify potential non-opioid and modified opioid antitussive agents.
  • To address the need for effective cough suppressants with improved safety profiles.

Main Methods:

  • Investigating the cough reflex mechanisms and sensitized cough pathways.
  • Developing novel opioid receptor agonists (kappa- and delta-selective).

Related Experiment Videos

  • Exploring non-opioid targets including nociceptin, neurokinin, bradykinin, and vanilloid receptor antagonists.

    • Main Results:

    • Identified potential therapeutic targets in the cough reflex pathways.
    • Developed novel opioid and non-opioid compounds.
    • Investigated agents like local anesthetics and channel blockers as cough reflex inhibitors.

    Conclusions:

    • Novel antitussive agents targeting various receptors and channels show promise.
    • These agents may act centrally, peripherally, or both.
    • Further clinical trials are needed to evaluate the efficacy and safety of these new compounds in humans.